Generic Name and Formulations:
Quinupristin/dalfopristin 500mg per vial (as 150mg quinupristin and 350mg dalfopristin); pwd for IV infusion after reconstitution; preservative-free.
Indications for SYNERCID:
Treatment of complicated skin and skin structure infections due to S. aureus (methicillin-susceptible) or S. pyogenes.
Give by IV infusion over 60mins. ≥16yrs: 7.5mg/kg every 12hrs for at least 7 days.
<16yrs: not established; doses of 7.5 mg/kg every 8hrs or 12hrs have been used in a limited number of children under emergency-use conditions (see full labeling).
Hepatic insufficiency. Pregnancy. Nursing mothers.
Avoid concomitant drugs known to prolong the QT interval. Potentiates CYP3A4 substrates (eg, midazolam, nifedipine, cisapride, carbamazepine, vinca alkaloids, taxanes, steroids, NNRTIs, protease inhibitors, statins); monitor esp. those with narrow therapeutic window (eg, cyclosporine, tacrolimus). May affect digoxin.
Inj site reactions, arthralgia, myalgia, GI upset, thrombophlebitis, rash, headache, pruritus; C. difficile-associated diarrhea.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Differences in Efficacy and Tolerability of ADHD Medications Across Age Groups
- Rapid Cycling Bipolar Disorder Associated With ADHD and Female Gender
- Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia
- Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
- Symptom Trajectories Vary According to Language Development in Autism
- Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations
- Selective Serotonin Reuptake Inhibitors May Increase Risk for Suboptimal Fetal Growth
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Prenatal Insecticide Exposure in Mother May Be Linked to Risk for Autism in Children